Literature DB >> 6256065

Activation of sodium cyanate for selective inhibition of protein synthesis in cultured tumor cells.

L C Boffa, S Kozak, V G Allfrey.   

Abstract

Sodium cyanate, a selective inhibitor of protein synthesis in animal tumors in situ, has no comparable effect when added to tumor cells in culture. However, a rapid inhibition of protein synthesis in cultured tumor cells can be achieved by reaction of cyanate with the drug-metabolizing system of liver microsomes. Procedures are described for the induction, preparation, and testing of an active cytochrome P-450 fraction which converts cyanate to a short-lived dialyzable metabolite that selectively inhibits amino acid incorporation in tumor cells without a corresponding effect on protein synthesis in normal cells. The suppression of tumor protein synthesis is not due to a general toxicity reaction because thymidine incorporation into the DNA of tumor cells is not inhibited by the cyanate metabolite. When HeLa cells are exposed to sodium butyrate, a substance reported to suppress the malignant phenotype in several tumor cell lines, they lose their sensitivity to the cyanate metabolite. Chick fibroblasts which are normally insensitive to the cyanate metabolite become cyanate sensitive after transformation by the Schmidt-Ruppin strain of the Rous sarcoma virus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6256065

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Cyanate-mediated inhibition of neutrophil myeloperoxidase activity.

Authors:  M Qian; J W Eaton; S P Wolff
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

2.  Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice.

Authors:  M Dufour; J St Germain; V Skalski; A Dorato; P Lazarus; L C Panasci
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Effects of sodium cyanate in mice bearing B16 melanoma.

Authors:  M A Lea; A Luke; O Velazquez; L Carpenter; C F Martinson; H Z Hill; G J Hill
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.